Company Overview - Impect is a global leader in soccer scouting analytics and tactical insights, founded in Germany in 2014 [2][3] - The company has developed a data-driven approach to scouting analysis, providing meaningful insights to teams and federations [2] Business Model and Operations - Impect generates tactical insights from over 40,000 matches across 25 countries, serving more than 150 teams [3] - The company operates an end-to-end intelligence platform that includes player scouting, opponent analysis, and internal benchmarking [3] - Impect utilizes proprietary packing data to enhance understanding of player performance [4] Acquisition Details - The acquisition of Impect is valued at an upfront consideration of EUR 40 million, approximately AUD 71 million or USD 46 million [4]

Group 1 - nDatalyze Corp. has announced that its sports analytics predictive scoring formulas, including genetic markers, are currently in testing and calibration [1] - The Epitome online questionnaire is now live and also undergoing testing, with data collection from three junior league teams expected to start in mid-October and conclude by year-end 2025 [1] - Machine learning has played a crucial role in the development of Epitome, significantly reducing costs and accelerating development time [1] Group 2 - The ongoing reverse takeover (RTO) process is in progress, with the controlling shareholder awaiting a tax opinion before finalizing the private placement amount [2] - Trading of the Corporation's shares will remain halted until the RTO is either completed or abandoned [2]

Core Insights - nDatalyze Corp. has launched "Epitome," a sports performance analytics project utilizing advanced machine learning to enhance professional hockey performance, tapping into a global sports analytics market projected to exceed USD $22 billion by 2030 [1][2] Value Proposition - Epitome employs proprietary biometric modeling technology to predict athletic performance, addressing a significant challenge in professional sports that could reduce risks and enhance returns for NHL franchises [2] - The project positions nDatalyze at the intersection of AI, genomics, and sports analytics, creating substantial commercial potential [2] Industry Demand & Economic Rationale - The inefficiencies in player drafting and development are highlighted, with only 19% of NHL draftees playing over 200 games, leading to significant financial losses [4] - The project aims to de-risk multimillion-dollar decisions in player selection by adapting clinically studied algorithms for sports applications [4] Progress & Strategic Positioning - Epitome reflects nDatalyze's commitment to commercializing its AI-driven biometric technology across high-value sectors, targeting a multi-billion dollar market with a clinically grounded solution [5] - The initiative is expected to deliver meaningful shareholder value and establish the company as a leader in predictive sports performance analytics [5] Signature Modeling - Epitome creates a unique "Signature" for each player by integrating biometric data, performance statistics, genetic predispositions, and algorithmic scores [6] - The system benchmarks individual Signatures against those of proven high-performance players to establish predictive metrics [6] - Applications include assessing future performance prospects, optimizing roster configurations, and developing personalized coaching protocols [6] Project Support and Financing - nDatalyze has secured commitments from three advisors, including former NHL coaches, to define the digital "high-performance player" [7] - The project is fully financed through existing cash, ensuring no dilution to shareholders at this stage [7] - Epitome is included in the proposed spinout related to the previously announced RTO, benefiting pre-RTO shareholders regardless of the RTO's closure [7]